PBYI News and Press, Puma Biotechnology Inc From 10/27/22

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer (NSCLC) patients at the EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Sym...

Summary Puma Biotechnology publicized a licensing deal for Takeda's alisertib, “a selective, small-molecule, orally administered inhibitor of aurora kinase A.” This has altered how I plan on managing my PBYI position. Puma announced the deal during one of the worst w...

Puma Biotechnology ( NASDAQ: PBYI ) on Tuesday said it had entered into a licensing agreement with Japanese pharmaceutical major Takeda ( NYSE: TAK ) for the development and commercialization of investigational cancer treatment alisertib. As per the terms of the de...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib i...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congre...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24 th Annual Global Investment Conference, w...

Puma Biotechnology (NASDAQ: PBYI) , a biopharmaceutical company that specializes in oncology therapies, saw its shares drop as much as 17.7% this week, according to data from S&P Global Intelligence . The stock closed at $3.10, then opened on Monday at that same price. T...

Puma Biotechnology, Inc. (PBYI) Q2 2022 Results Conference Call August 04, 2022 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer ...

Puma Biotechnology press release ( NASDAQ: PBYI ): Q2 Non-GAAP EPS of $0.28. Revenue of $59.5M (+11.4% Y/Y). At June 30, 2022, Puma had cash, cash equivalents and marketable securities of $60.8M, compared to cash, cash equivalents and marketable securities of $82.1M at...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Unless otherwise stated, all comparisons are for the second quarter of 2022 compared to the second quarter of 2021. Product revenue, net cons...